

Vanguard 7

Not
authorised

- Canine parainfluenza virus, strain NL-CPI-5, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine distemper virus, strain Snyder Hill, Live
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
- Canine parvovirus, strain NL-35-D, Live

Product identification

Medicine name:

Vanguard 7

Active substance:

Canine parainfluenza virus, strain NL-CPI-5, Live

Canine adenovirus 2, strain Manhattan, Live

Canine distemper virus, strain Snyder Hill, Live

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated

Canine parvovirus, strain NL-35-D, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine parainfluenza virus, strain NL-CPI-5, Live

1000000.00 50% tissue culture infectious dose / 1.00 Dose

Canine adenovirus 2, strain Manhattan, Live

1585.00 50% tissue culture infectious dose / 1.00 Dose

Canine distemper virus, strain Snyder Hill, Live

1000.00 50% tissue culture infectious dose / 1.00 Dose

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar

Icterohaemorrhagiae, strain NADL 11403, Inactivated

40.00 Hamster protective Dose 80% / 1.00 millilitre(s)

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated

40.00 Hamster protective Dose 80% / 1.00 millilitre(s)

Canine parvovirus, strain NL-35-D, Live

10000000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:**Subcutaneous use:**

-

Dog

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Surrendered

Authorised in:

Germany

Package description:

Available only in [German](#)

Available only in [German](#)

Available only in [German](#)

Available only in [German](#)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Deutschland GmbH

Marketing authorisation date:

2/01/2006

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

Paul-Ehrlich-Institut

Authorisation number:

8a/91

Date of authorisation status change:

6/06/2024

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 12/01/2023

[Download](#)